



# Biotech Daily

Monday January 2, 2023

*Special Edition*

**GOOD BYE 2022, HELLO 2023**

**BDI-40 DOWN 21%; NBI DOWN 11% ASX200 DOWN 5.5% BIG CAPS DOWN 5%**

***Four cheers for: Neuren Up 113% Polynovo Up 34.5%, Oncosil 30.6%, Telix 2.45%***

The last turn of the Sun was not great for the Biotech Daily Top-40 Index (BDI-40), the benchmark S&P ASX200, the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40), Cannabis Corner or the Nasdaq Biotechnology Index (NBI).

All these indices fell in December and for the year. The December BDI-40 lost 7.3 percent to a collective market capitalization of \$17,789 million, closing the year down 21.0 percent.

The ASX200 shed 3.4 percent in December and 5.5 percent for the year, the three Big Caps fell 5.2 percent in December and 4.9 percent the year, while the NBI closed 2022 down 10.9 percent.

The 11 companies in Cannabis Corner shed 12.0 percent in December to a collective market capitalization of \$903 million, 33.75 percent below the close of 2021.

All three Big Caps were down in December and for the year. Resmed led the falls, down 13.1 percent to \$45,479 million, followed by Cochlear down 7.1 percent to \$13,388 million and CSL down \$6,949 million (4.8%) in the month of December and 1.6 percent for the year to \$137,769 million.

Just four of the BDI-40 stocks were up in 2022; with 12 down by 50 percent or more, nine were down by 40-50%; five lost 30-40% and 10 were down by less than 30 percent.

The four heroes were Neuren - up 113.1 percent to \$1,012 million - followed by Polynovo (34.5%), Oncosil (30.6%) and Telix (2.45%).

Imugene fell below \$1 billion for the first time since May 31, 2021 having peaked at \$3,139 million on November 30, 2021 and closing 2022 at \$867 million.

But the worst for 2022 was Kazia, losing 91.0 percent of its market capitalization to just \$15 million, followed by Atomo (74.8%), Universal Biosensors (72.7%), Medical Developments (64.0%), Imugene (62.4%) Uscom (60.9%), Starpharma (57.1%), Resonance (56.9%), Impedimed (54.7%) and Genetic Signatures (50.8%) with Amplia and Antisense both down 50 percent for the year.


We're not trying to gild the ungildable, but it is worth noting that the ASX200 is just 0.3 percent above the immediate pre-Covid January 31, 2020 level, while the BDI-40 is 6.0 percent above that record-high time-point.

Always look on the bright side of life, Brian.


Outside the BDI-40, Anteris, Aroa, Botanix, Clarity, Cronos, Cryosite and Living Cell were the few to climb during 2022.

Botanix and Cronos were the only good news in Cannabis Corner, while Incannex lost \$485 million or 64.2 percent to \$270 million. Zelira had the deepest percentage fall for the year, down 76.2 percent, followed by Medlab (70.6%), Creso (63.4%), with Auscann and Epsilon both down 50 percent for the year.

**BDI-40 v ASX200 Jun 30, 2006 to Dec 31, 2022- Adjusted**



**Big Caps \$m (Cochlear, CSL, Resmed) Dec 31, 2017 – Dec 31, 2022**



## Biotech Daily Top 40 with Market Capitalization At December 31, 2022

Company \$Am	Jan-22	Dec-22	Jan-23
Cochlear	14,405	13,786	13,388
CSL	140,034	144,718	137,769
Resmed	52,309	48,999	45,479
<b>BDI-20</b>			
Avita	426	236	247
Clinuvel	1,412	968	1,066
Compumedics	66	38	35
Cyclopharm	153	123	109
Cynata	78	49	43
Genetic Signatures	256	130	126
Immutep	419	325	242
Kazia	166	14	15
Medical Developments	356	138	128
Mesoblast	882	815	638
Nanosonics	1,934	1,432	1,287
Neuren	475	1,008	1,012
Nova Eye	47	44	41
Opthea	479	447	427
Pharmaxis	66	40	44
Polynovo	1,002	1,369	1,348
Pro Medicus	6,569	6,207	5,648
Starpharma	525	204	225
Telix	2,164	2,325	2,217
Volpara	262	124	132
<b>Second 20</b>			
Actinogen	284	198	181
Alcidion	336	200	184
Amplia	32	19	16
Antisense	130	57	65
Atomo	123	33	31
Dimerix	79	50	47
Emvision	207	165	144
Impedimed	311	164	141
Imugene	2,306	1,181	867
Micro-X	117	66	67
Next Science	246	140	147
Oncosil	36	48	47
Orthocell	101	90	81
Paradigm	431	395	393
Patrys	76	53	56
Prescient	150	104	97
Proteomics	128	102	110
Resonance	65	28	28
Universal Biosensors	176	50	48
Uscom	23	10	9

\* Biotech Daily editor, David Langsam, owns shares in Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Pharmaxis, Polynovo, Telix, Volpara and non-biotech stocks. Through Australian Ethical Superannuation he has an indirect interest in other companies: <https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/>. These holdings are liable to change.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053**  
**email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au); twitter: @biotech\_daily**